Prot# 248.616: A Phase IV Randomised, Double-Blind, Active and Placebo-Controlled, 6-Week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients with Idiopathic Restless Legs Syndro

Project: Research project

Project Details

StatusFinished
Effective start/end date1/10/079/30/08

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (248.616)